安旭生物(688075.SH)：预计2025年净利润同比减少55.80%到63.08%

Core Viewpoint - Anxu Bio (688075.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 55.80% to 63.08% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decrease of 58.84% to 65.70% [1] Business Development - The company's main business remains stable, and it continues to invest strategically in new technology platforms while maintaining the advancement of existing ones [1] - Efforts to expand in domestic and international markets, as well as obtaining registration certificates, have led to increased expenses [1] External Factors - The increase in tariffs imposed by the U.S. government has resulted in a reduction of orders in certain regional markets, contributing to higher operating costs for the company [1] - Additional factors affecting profit include exchange rate fluctuations leading to foreign exchange losses, reduced interest income, and depreciation and amortization of assets [1]